Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 18/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404367 | 1.00 | P2RX7 (0.57) | P2RX7KDM4EMAPTCLK1ALDH1A1 | |
| SCHEMBL6402622 | 0.96 | P2RX7 (0.57) | P2RX7KDM4EMAPTCLK1ALDH1A1 | |
| SCHEMBL6402621 | 0.96 | P2RX7 (0.57) | P2RX7KDM4EMAPTCLK1ALDH1A1 | |
| SCHEMBL6402297 | 0.95 | P2RX7 (0.57) | P2RX7KDM4EMAPTCLK1ALDH1A1 | |
| SCHEMBL6404281 | 0.95 | P2RX7 (0.57) | P2RX7KDM4EMAPTCLK1ALDH1A1 | |
| SCHEMBL6400150 | 0.89 | P2RX7 (0.71) | P2RX7KDM4EMAPTCLK1ALDH1A1 | |
| SCHEMBL6401825 | 0.89 | P2RX7 (0.71) | P2RX7KDM4EMAPTALDH1A1 | |
| SCHEMBL6401824 | 0.89 | P2RX7 (0.71) | P2RX7KDM4EMAPTALDH1A1 | |
| SCHEMBL6408980 | 0.89 | P2RX7 (0.71) | P2RX7KDM4EMAPTCLK1ALDH1A1 | |
| SCHEMBL6400149 | 0.89 | P2RX7 (0.71) | P2RX7KDM4EMAPTCLK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | claimed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885KDM4E 3084/4885MAPT 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.